• Citer

Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial

par Lambertini, Matteo ;Poggio, Francesca;Bruzzone, Marco;Conte, Benedetta;Bighin, Claudia;de Azambuja, Evandro ;Giuliano, Mario;De Laurentiis, Michele;Cognetti, Franscesco;Fabi, Alessandra;Bisagni, Giancarlo;Durando, Antonio;Turletti, Anna;Urracci, Ylenia;Garrone, Ornella;Puglisi, Fabio;Montemurro, Filippo;Ceppi, Marcello;Del Mastro, Lucia
Référence International journal of cancer
Publication Publié, 2019-12-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial
Auteur:	Lambertini, Matteo; Poggio, Francesca; Bruzzone, Marco; Conte, Benedetta; Bighin, Claudia; de Azambuja, Evandro; Giuliano, Mario; De Laurentiis, Michele; Cognetti, Franscesco; Fabi, Alessandra; Bisagni, Giancarlo; Durando, Antonio; Turletti, Anna; Urracci, Ylenia; Garrone, Ornella; Puglisi, Fabio; Montemurro, Filippo; Ceppi, Marcello; Del Mastro, Lucia
Informations sur la publication:	International journal of cancer
Statut de publication:	Publié, 2019-12-01
Sujet CREF:	Cancérologie
Mots-clés:	adjuvant chemotherapy
	breast cancer
	dose-dense
	HER2
	trastuzumab
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0020-7136
	info:doi/10.1002/ijc.32789
	info:scp/85076096981
	info:pmid/31724170